A Prospective Study of The Complement Depletion in Patients With Severe Abdominal Sepsis

Sponsor
Jinling Hospital, China (Other)
Overall Status
Completed
CT.gov ID
NCT01568853
Collaborator
(none)
75
1
4
18.9

Study Details

Study Description

Brief Summary

The role of complement system in bridging innate and adaptive immunity has been confirmed in various invasive pathogens. The aim of this study is to investigate the alteration of complement C3 in patients with severe abdominal sepsis and evaluate the role of complement C3 depletion in prognosis of such patients. The relationship between complement C3 depletion and adaptive immunity is studied meanwhile.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Severe abdominal sepsis remains a significant cause of death in patients undergoing intra-abdominal infection, in despite of recent declines in overall mortality. There is a abundant evidence to suggest complement activation during sepsis. While there is great interest in complement by-products in human sepsis, few studies focus on the persistent consumption of complement components and its role in prognosis of sepsis. Complement C3 is indispensable community pathway for complement activation. In a way, the alteration of C3 levels can affect the whole status of complement biological functions.

In clinical practice, the severe abdominal sepsis would develop compromised immune function if the intra-abdominal infection is not well controlled. The down-regulated T- and B-cell immune responses to sepsis are correlated to the decreased immune defense. To our knowledge, there are few human data that have investigated the relationship between complement depletion and adaptive immunity in severe abdominal sepsis. The investigators hypothesize that the complement C3 depletion during sepsis has a stronger association with the down-regulated adaptive immunity and can be regarded as a essential risk factor to predict the prognosis of such critical illness.

The purpose of this prospective study is two-fold. First, the investigators observe, in a cohort of patients with severe abdominal sepsis, the levels of complement components and percentages of T cell subsets after admission to evaluate the relationship between complement system and adaptive immunity. Second, the investigators also evaluate the application of the C3 related-indexes (C3, C3a, Factor H, DAF, etc.) to patients undergoing severe abdominal sepsis and to develop an alternative model to predict its prognosis.

Study Design

Study Type:
Interventional
Actual Enrollment :
75 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
The Complement C3 Depletion in Patients With Severe Abdominal Sepsis: Risk Prediction and the Association With Down-regulated Adaptive Immunity
Study Start Date :
Nov 1, 2011
Actual Primary Completion Date :
Mar 1, 2012
Actual Study Completion Date :
Mar 1, 2012

Outcome Measures

Primary Outcome Measures

  1. All cause mortality [within the first 28 days after admission to our hosptial]

    Patients died within the first three days of admission would be excluded from this study.

Secondary Outcome Measures

  1. Postoperative complications [within the first 28 days after admission to our hosptial]

    wound complications; pulmonary infection; incisional hernia, and bleeding.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical diagnosis of severe abdominal sepsis
Exclusion Criteria:
  • Age < 18 or > 60 years

  • Pregnancy

  • Leucopenia from radiochemical therapy due to malignant tumor

  • Any primary diagnosis other than sepsis

  • Confirmed immunodeficiency

  • Requirement for blood transfusion, plasmapheresis, or immediate surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Surgery, Jinling Hospital Nanjing Jiangsu China 210002

Sponsors and Collaborators

  • Jinling Hospital, China

Investigators

  • Principal Investigator: Jianan Ren, M.D., Department of Surgery, Jinling Hospital, China

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jianan Ren, Clinical professor, Principal investigator, Jinling Hospital, China
ClinicalTrials.gov Identifier:
NCT01568853
Other Study ID Numbers:
  • BK2010-017-1
First Posted:
Apr 2, 2012
Last Update Posted:
Apr 6, 2012
Last Verified:
Apr 1, 2012

Study Results

No Results Posted as of Apr 6, 2012